GoodRx Holdings, Inc. (NASDAQ:GDRX) Major Shareholder Equity Vii L.P. Spectrum Sells 10,677 Shares of Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

GoodRx Stock Down 0.5 %

Shares of GDRX stock traded down $0.04 on Tuesday, hitting $7.86. 1,041,923 shares of the stock were exchanged, compared to its average volume of 1,492,681. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.96. The firm has a market capitalization of $2.95 billion, a P/E ratio of -794.00, a price-to-earnings-growth ratio of 3.74 and a beta of 1.39. The business has a 50-day moving average of $8.04 and a 200 day moving average of $7.53. GoodRx Holdings, Inc. has a fifty-two week low of $4.14 and a fifty-two week high of $9.26.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The firm had revenue of $200.60 million for the quarter, compared to analyst estimates of $200.47 million. During the same period in the prior year, the company earned $0.02 earnings per share. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. Equities analysts anticipate that GoodRx Holdings, Inc. will post 0.15 EPS for the current year.

Institutional Trading of GoodRx

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cornercap Investment Counsel Inc. raised its stake in GoodRx by 1.7% in the second quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock valued at $587,000 after buying an additional 1,266 shares during the period. California State Teachers Retirement System raised its stake in GoodRx by 5.1% in the first quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock valued at $503,000 after buying an additional 3,444 shares during the period. US Bancorp DE grew its position in shares of GoodRx by 3.7% in the first quarter. US Bancorp DE now owns 109,818 shares of the company’s stock valued at $780,000 after purchasing an additional 3,877 shares during the last quarter. Beacon Capital Management LLC acquired a new position in shares of GoodRx in the first quarter valued at approximately $28,000. Finally, Plato Investment Management Ltd acquired a new position in shares of GoodRx in the second quarter valued at approximately $43,000. Institutional investors own 63.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on GDRX shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price objective on shares of GoodRx in a research report on Friday, August 16th. Citigroup dropped their target price on GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th. TD Cowen boosted their target price on GoodRx from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, May 16th. Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price for the company in a research report on Friday, August 9th. Finally, UBS Group dropped their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.36.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.